company background image
CVM logo

CEL-SCI NYSEAM:CVM Stock Report

Last Price

US$1.89

Market Cap

US$102.0m

7D

-4.5%

1Y

-17.8%

Updated

27 Mar, 2024

Data

Company Financials +

CVM Stock Overview

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States.

CVM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CEL-SCI Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CEL-SCI
Historical stock prices
Current Share PriceUS$1.89
52 Week HighUS$3.23
52 Week LowUS$1.04
Beta1.32
1 Month Change-6.44%
3 Month Change-33.45%
1 Year Change-17.83%
3 Year Change-87.57%
5 Year Change-59.09%
Change since IPO-99.98%

Recent News & Updates

Recent updates

Market Sentiment Around Loss-Making CEL-SCI Corporation (NYSEMKT:CVM)

Apr 29
Market Sentiment Around Loss-Making CEL-SCI Corporation (NYSEMKT:CVM)

We Think CEL-SCI (NYSEMKT:CVM) Can Afford To Drive Business Growth

Mar 01
We Think CEL-SCI (NYSEMKT:CVM) Can Afford To Drive Business Growth

What Does CEL-SCI's (NYSEMKT:CVM) CEO Pay Reveal?

Jan 25
What Does CEL-SCI's (NYSEMKT:CVM) CEO Pay Reveal?

Breakeven On The Horizon For CEL-SCI Corporation (NYSEMKT:CVM)

Dec 21
Breakeven On The Horizon For CEL-SCI Corporation (NYSEMKT:CVM)

Shareholder Returns

CVMUS BiotechsUS Market
7D-4.5%0.9%0.4%
1Y-17.8%10.3%28.8%

Return vs Industry: CVM underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: CVM underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is CVM's price volatile compared to industry and market?
CVM volatility
CVM Average Weekly Movement10.4%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CVM's share price has been volatile over the past 3 months.

Volatility Over Time: CVM's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1983n/aGeert Kerstenhttps://cel-sci.com

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer.

CEL-SCI Corporation Fundamentals Summary

How do CEL-SCI's earnings and revenue compare to its market cap?
CVM fundamental statistics
Market capUS$102.02m
Earnings (TTM)-US$31.05m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CVM income statement (TTM)
RevenueUS$0
Cost of RevenueUS$21.43m
Gross Profit-US$21.43m
Other ExpensesUS$9.62m
Earnings-US$31.05m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.58
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CVM perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.